All Stories

  1. Immune thrombocytopenia: improving quality of life and patient outcomes
  2. The diagnosis and management of primary autoimmune haemolytic anaemia
  3. Donors With Immune Thrombocytopenia: Do They Pose a Risk to Transplant Recipients?
  4. A United Kingdom Immune Thrombocytopenia (ITP) Forum review of practice: thrombopoietin receptor agonists
  5. Autoimmune haemolytic anaemia
  6. Autoimmune hemolytic anemia
  7. How does dapsone work in immune thrombocytopenia? Implications for dosing
  8. Fatigue in immune thrombocytopenia
  9. Disappointing response to dapsone as second line therapy for primary ITP: a case series
  10. Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis
  11. Haematology in Critical Care
  12. A combination of two novel alpha globin variants Hb Bridlington (HBA1) and Hb Taybe (HBA2) resulting in severe hemolysis, pulmonary hypertension, and death
  13. High Blood Counts
  14. Leukopenia
  15. Understanding the Blood Film
  16. Haematological Emergencies
  17. Diagnostic Approach to Anaemia in Critical Care
  18. Appendix A
  19. Decisions to Intensify Treatment
  20. The diagnostic challenge of congenital dyserythropoietic anaemia: two cases of ‘CDA type II’
  21. Unsuccessful stem cell remobilization for autologous transplantation is predicted by renal impairment and a stem cell yield 0.5 × 106 CD34+ cells/kg at first mobilization
  22. The importance of CD4 count, viral load and highly active antiretroviral therapy in HIV-associated thrombotic thrombocytopenic purpura (TTP): Figure 1
  23. Survival of patients with hematological malignancy admitted to the intensive care unit: prognostic factors and outcome compared to unselected medical intensive care unit admissions, a parallel group study
  24. Intensify, resuscitate or palliate: Decision making in the critically ill patient with haematological malignancy
  25. Towards better blood transfusion - recruitment and training
  26. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation
  27. An analysis of the optimal timing of peripheral blood stem cell harvesting following priming with cyclophosphamide and G-CSF
  28. CNS prophylaxis in lymphoma: Who to target and what therapy to use